Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend
Remus Pharmaceuticals Ltd 路 Intimation 路 03 Nov 2026, 5:30 am
Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend Remus Pharmaceuticals Limited has scheduled a Board of Directors meeting for 3rd Nov'26. The board will consider and approve the unaudited standalone and consolidated financial results for the half-year ended 30th Sep'26, accompanied by the limited review report. Additionally, the board will evaluate a proposal to declare a 1st interim dividend on equity shares for FY27. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 until 48 hours post-result declaration.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript 路 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
